Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Annexon Inc (ANNX)

Annexon Inc (ANNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 769,161
  • Shares Outstanding, K 105,654
  • Annual Sales, $ 0 K
  • Annual Income, $ -134,240 K
  • EBIT $ -127 M
  • EBITDA $ -125 M
  • 60-Month Beta 1.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.87

Options Overview Details

View History
  • Implied Volatility 70.30% ( -6.02%)
  • Historical Volatility 50.64%
  • IV Percentile 17%
  • IV Rank 14.67%
  • IV High 418.72% on 05/17/24
  • IV Low 10.42% on 08/13/24
  • Put/Call Vol Ratio 9.41
  • Today's Volume 177
  • Volume Avg (30-Day) 228
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 6,166
  • Open Int (30-Day) 6,518

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.26
  • Number of Estimates 5
  • High Estimate -0.22
  • Low Estimate -0.31
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +39.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.05 +17.19%
on 10/08/24
7.85 -9.68%
on 10/18/24
+0.80 (+12.72%)
since 10/04/24
3-Month
5.22 +35.82%
on 08/05/24
7.85 -9.68%
on 10/18/24
+1.12 (+18.76%)
since 08/02/24
52-Week
2.05 +246.70%
on 11/10/23
8.40 -15.60%
on 03/27/24
+4.50 (+173.75%)
since 11/03/23

Most Recent Stories

More News
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

ANNX : 7.09 (-2.61%)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

ANNX : 7.09 (-2.61%)
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

ANNX : 7.09 (-2.61%)
Stock Index Futures Slip on Growth Fears, U.S. JOLTs Report in Focus

June S&P 500 E-Mini futures (ESM24) are down -0.36%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.34% this morning after weak manufacturing data raised concerns about the U.S. economic health,...

ESM24 : 5,471.89s (-0.09%)
NQM24 : 19,747.29s (-0.08%)
PARA : 10.87 (-1.00%)
NVDA : 136.05 (+0.48%)
BA : 155.07 (+0.31%)
SAIC : 146.14 (+1.02%)
FANG : 179.76 (+2.25%)
DVN : 39.15 (+2.17%)
CRWD : 298.88 (-1.40%)
FERG : 198.14 (+0.08%)
PVH : 100.38 (+1.95%)
HPE : 20.01 (-0.25%)
Why Shares of Annexon Are Plummeting Thursday

Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.

ISEE : 39.95 (+0.38%)
APLS : 28.56 (+2.07%)
ALPMY : 11.7100 (+0.43%)
ANNX : 7.09 (-2.61%)
Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results

Advancing Robust Pipeline of Five Clinical-Stage Product Candidates Following ANX105 and ANX1502 Phase 1 Trial Initiations Multiple Clinical Readouts...

ANNX : 7.09 (-2.61%)
Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025

Proceeds Support Advancement of Broad Pipeline of Novel Complement Product Candidates for Diseases of the Body, Brain and Eye...

ANNX : 7.09 (-2.61%)
Annexon Announces $130 Million Private Placement Financing

BRISBANE, Calif., July 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...

ANNX : 7.09 (-2.61%)
Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease

ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated Disease Progression Stabilized in Overall Patient Population Through the...

ANNX : 7.09 (-2.61%)
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference

BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...

ANNX : 7.09 (-2.61%)

Business Summary

Annexon Inc. is a clinical-stage biopharmaceutical company. It engages in developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company's product candidate includes ANX005 and ANX007, which are in clinical stage. Annexon Inc....

See More

Key Turning Points

3rd Resistance Point 7.84
2nd Resistance Point 7.59
1st Resistance Point 7.34
Last Price 7.09
1st Support Level 6.85
2nd Support Level 6.60
3rd Support Level 6.35

See More

52-Week High 8.40
Last Price 7.09
Fibonacci 61.8% 5.97
Fibonacci 50% 5.22
Fibonacci 38.2% 4.47
52-Week Low 2.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar